@article{GS16202,
author = {Bridget A. Oppong and Surupa Sen Gupta and Monique Gary and Patricia Wehner and Mihriye Mete and Danjing Zhao and Sulakshana Seevaratnam and Sonali Rudra and Shawna C. Willey},
title = {21-gene recurrence assay in patients receiving intraoperative radiotherapy: are “favorable” characteristics a surrogate for low recurrence?},
journal = {Gland Surgery},
volume = {6},
number = {6},
year = {2017},
keywords = {},
abstract = {Background: Intraoperative radiotherapy (IORT) has gained momentum for early stage and favorable breast cancers (BC). The 21-gene recurrence assay guides treatment of hormone positive and node-negative BC.
Methods: Analysis of 82 invasive BC treated with breast conservation surgery (BCS) and IORT 2013–2015. Data collection included patient demographics, tumor characteristics, nodal status, recurrence test (RS) and adjuvant therapy.
Results: The mean age was 68. Tumors were stage Ia (86.6%), 3.6% Ib and 9.8% IIa. Of 50 patients (61.0%) with RS testing, 72% (n=36) were low risk (RS 0–17), with 28% (n=14) at intermediate risk (RS 18–30). The 39% (n=32) of patients without RS testing, were more likely to have smaller tumors (1.3 vs. 0.9 cm) and age >70 (P},
issn = {2227-8575}, url = {https://gs.amegroups.org/article/view/16202}
}